Molecular mechanisms of steroid hormone action

Endocrine-Related Cancer

Volumn 5, Issue 1, 1998, Pages 1-14

  White, R ^a   Parker, M G ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; FLUTAMIDE; FULVESTRANT; STEROID HORMONE; STEROID RECEPTOR; TAMOXIFEN;

CELL PROLIFERATION; DRUG RECEPTOR BINDING; ENDOCRINE DISEASE; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HORMONE ACTION; LIGAND BINDING; NEUROTRANSMITTER RELEASE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSACTIVATION;

EID: 0031971764     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0050001     Document Type: Review

References (108)

1. Ali S, Metzger D, Bornert J-M & Chambon P 1993 Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO Journal 12 1153-1160.
2. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F & Weisz A 1996 17-beta-estradiol induces cyclin d-1 gene-transcription, p36(d1)-p34(cdk4) complex activation and p105(rb) phosphorylation during mitogenic stimulation of g(1)-arrested human breast-cancer. Oncogene 12 2315-2324.
3. Angel P & Karin M 1991 The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochimica et Biophysica Acta 1072 129-157.
4. Arnold SF, Obourn JD, Jaffe H & Notides AC 1995 Phosphorylation of the human estrogen receptor on tyrosine-537 in vivo and by Src family tyrosine kinases in vitro. Molecular Endocrinology 9 24-33.
5. Aronica SM & Katzenellenbogen B 1993 Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Molecular Endocrinology 7 743-752.
6. Barettino D, Ruiz MDMV & Stunnenberg HG 1994 Characterization of the ligand-dependent transactivation domain of thyroid-hormone receptor. EMBO Journal 13 3039-3049.
7. vom Baur E, Zechel C, Heery D, Heine MJS, Garnier JM, Vivat V, Le Douarin B, Gronemeyer H, Chambon P & Losson R 1996 Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO Journal 15 110-124.
8. Beato M 1989 Gene regulation by steroid hormones. Cell 56 335-344.
9. Berry M, Metzger D & Chambon P 1990 Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the antioestrogen 4-hydroxytamoxifen. EMBO Journal 9 2811-2818.
10. Bocchinfuso WP & Korach KS 1997 Biological impact of a disrupted estrogen receptor gene on estrogen-related cancer. Endocrine-Related Cancer 4 387-406.
11. Bohen SP, Kralli A & Yamamoto KR 1995 Hold 'em and fold 'em: chaperons and signal transduction. Science 268 1303-1304.
12. Bourguet W, Ruff M, Chambon P, Gronemeyer H & Moras D 1995 Crystal-structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature 375 377-382.
13. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson J-Å & Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 753-758.
14. Bunone G, Briand P-A, Miksicek RJ & Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 15 2174-2183.
15. Cavaillès V, Dauvois S, Danielian PS & Parker MG 1994 Interaction of proteins with transcriptionally active estrogen receptors. Proceedings of the National Academy of Sciences of the USA 91 10009-10013.
16. Cavaillès V, Dauvois S, L'Horset F, Lopez G, Hoare S, Kushner PJ & Parker MG 1995 Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO Journal 14 3741-3751.
17. Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M & Evans RM 1996 Role of CBP/ P300 in nuclear receptor signalling. Nature 383 99-103.
18. Chen JY, Penco S, Ostrowski J, Balaguer P, Pons M, Starrett JE, Reczek P, Chambon P & Gronemeyer H 1995 Rar-specific agonist/antagonists which dissociate transactivation and AP-1 transrepression inhibit anchorage-independent cell-proliferation. EMBO Journal 14 1187-1197.
19. Clarke R, Dickson RB & Lippman ME 1991 The role of steroid hormones and growth factors in the control of normal and malignant breast. In Nuclear Hormone Receptors, pp 297-319. Ed. M Parker. London: Academic Press.
20. Curtis SW, Washburn T, Sewall C, Diaugustine R, Lindzey J, Couse JF & Korach KS 1996 Physiological coupling of growth-factor and steroid-receptor signaling pathways - estrogen-receptor knockout mice lack estrogen-like response to epidermal growth-factor. Proceedings of the National Academy of Sciences of the USA 93 12626-12630.
21. Danielian PS, White R, Lees JA & Parker MG 1992 Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO Journal 11 1025-1033.
22. Danielian PS, White R, Hoare SA, Fawell SE & Parker MG 1993 Identification of residues in the estrogen receptor which confer differential sensitivity to estrogen and hydroxytamoxifen. Molecular Endocrinology 7 232-240.
23. Dauvois S & Parker MG 1993 Mechanism of action of hormone antagonists. In Steroid Hormone Action, pp 161-185. Ed. M Parker. Oxford: IRL Press.
24. Dauvois S, Danielian PS, White R & Parker MG 1992 Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proceedings of the National Academy of Sciences of the USA 89 4037-4041.
25. Dauvois S, White R & Parker MG 1993 The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. Journal of Cell Science 106 1377-1388.
26. Diamond MI, Miner JN, Yoshinaga SK & Yamamoto KR 1990 Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249 1266-1272.
27. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD & Arnaud C 1996 A controlled trial of raloxifene (LY139481) HCI - impact on bone turnover and serum-lipid profile in healthy postmenopausal women. Journal of Bone and Mineral Research 11 835-842.
28. Durand B, Saunder M, Gaudon C, Roy B, Losson R & Chambon P 1994 Activation function 2 (AF-2) of retinoic acid receptor and 9-cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF-2 activity. EMBO Journal 13 5370-5382.
29. Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240 889-895.
30. Fawell SE, Lees JA, White R & Parker MG 1990a Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 60 953-962.
31. Fawell SE, White R, Hoare S, Sydenham M, Page M & Parker MG 1990b Inhibition of estrogen receptor-DNA binding by the 'pure' antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proceedings of the National Academy of Sciences of the USA 87 6883-6887.
32. Fuqua SAW 1994 Estrogen receptor mutagenesis and hormone resistance. Cancer 74 1026-1029.
33. Fuqua SAW, Wiltschke C, Castles C, Wolf D & Allred DC 1995 A role for estrogen-receptor variants in endocrine resistance. Endocrine Related Cancer 2 19-25.
34. Gaub M-P, Bellard M, Scheuer I, Chambon P & Sassone-Corsi P 1990 Activation of the ovalbumin gene by the estrogen receptor involves the Fos-Jun complex. Cell 63 1267-1276.
35. Gibson MK, Nemmers LA, Beckman Jr WC, Davis VL, Curtis SW & Korach KS 1991 The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129 2000-2010.
36. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C & Brown M 1994 Estrogen receptor-associated proteins -possible mediators of hormone-induced transcription. Science 264 1455-1458.
37. Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Kurokawa R & Brown M 1996 p300 is a component of an estrogen receptor coactivator complex. Proceedings of the National Academy of Sciences of the USA 93 11540-11545.
38. Heery DM & Parker MG 1997 Ligand induced transcription by nuclear receptors. Retinoids 13 26-30.
39. Heery DM, Kalkhoven E, Hoare S & Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387 733-736.
40. Heinzel T, Lavinsky RM, Mullen T-M, Soderstrom M, Laherty CD, Torchia J, Yang W-M, Brard G, Ngo SD, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK & Rosenfeld MG 1997 A complex containing N-Cor, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387 43-48.
41. Henttu PMA, Kalkhoven E & Parker MG 1997 AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors. Molecular and Cellular Biology 17 1832-1839.
42. Hong H, Kohli K, Trivedi A, Johnson DL & Stallcup MR 1996 Gripl, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone-binding domains of steroid-receptors. Proceedings of the National Academy of Sciences of the USA 93 4948-4952.
43. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK & Rosenfeld MG 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor corepressor. Nature 377 397-404.
44. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimaoto GS & Tung L 1996 Nuclear receptor coactivators and corepressors. Molecular Endocrinology 10 1167-1177.
45. Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, McLachlan JA & Korach KS 1992 Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proceedings of the National Academy of Sciences of the USA 89 4658-4662.
46. Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS & McLachlan JA 1993 Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Molecular Endocrinology 7 992-998.
47. Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA & Korach KS 1996 Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 137 1735-1744.
48. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L & Horwitz KB 1997 The partial agonist activity of antagonist occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-Cor or SMRT. Molecular Endocrinology 11 693-705.
49. Jafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan Jr TR, Lubahn DB, O'Donnell Jr TF, Korach KS & Mendelsohn ME 1997 Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice. Nature Medicine 3 545-548.
50. Janknecht R & Hunter T 1996 A growing coactivator network. Nature 383 22-23.
51. Jobling S, Reynolds T, White R, Parker MG & Sumpter JP 1995 A variety of environmentally persistent chemicals, including some phthalate plasticizers, are weakly estrogenic. Environmental Health Perspectives 103 582-587.
52. Jordan VC, Catherino WH & Wolf DM 1995 A mutant receptor as a mechanism of drug resistance to tamoxifen treatment. Annals of the New York Academy of Sciences 761 138-147.
53. Joyeux A, Cavaillés V, Balaguer P & Nicolas JC 1996 RIP 140 enhances nuclear receptor-dependent transcription in vivo, in yeast. Molecular Endocrinology 11 193-202.
54. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin S-C, Heyman RA, Rose DW, Glass CK & Rosenfeld MG 1996 A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85 403-414.
55. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D & Chambon P 1995 Activation of the estrogen-receptor through phosphorylation by mitogen-activated protein-kinase. Science 270 1491-1494.
56. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S & Gustafsson J-A 1996 Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proceedings of the National Academy of Sciences of the USA 93 5925-5930.
57. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S & Gustafsson J-A 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 183 863-870.
58. Kumar V & Chambon P 1988 The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55 145-156.
59. Le Douarin B, Zechel C, Garnier JM, Lutz Y, Tora L, Pierrat B, Heery D, Gronemeyer H, Chambon P & Losson R 1995 The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO Journal 14 2020-2033.
60. Le Douarin B, Nielsen AL, Garnier J-M, Ichinose H, Jeanmougin F, Losson R & Chambon P 1996 A possible involvement of TIF1α and TIF1β in the epigenetic control of transcription by nuclear receptors. EMBO Journal 15 6701-6715.
61. Lee JW, Ryan F, Swaffield JC, Johnston SA & Moore DD 1995 Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature 374 91-94.
62. Lees JA, Fawell SE & Parker MG 1989 Identification of two transactivation domains in the mouse oestrogen receptor. Nucleic Acids Research 17 5477-5488.
63. L'Horset F, Dauvois S, Heery DM, Cavaillés V & Parker MG 1996 RIP-140 interacts with multiple nuclear receptors by means of two distinct sites. Molecular and Cellular Biology 16 6029-6036.
64. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P & Evans RE 1995 The nuclear receptor superfamily: the second decade. Cell 83 835-839.
65. Metzger D, Berry M, Ali S & Chambon P 1995 Effect of antagonists on DNA-binding properties of the human estrogen-receptor in vitro and in vivo. Molecular Endocrinology 9 579-591.
66. Mosselman S, Polman J & Dijkema R 1996 ERβ: identification and characterization of a novel human estrogen receptor. FEBS Letters 392 49-53.
67. Musgrove EA & Sutherland RL 1994 Cell cycle control by steroid hormones. In: Seminars in Cancer Biology vol 5, pp 381-389. Ed. M Parker. London: Academic Press.
68. Nagy L, Kao H-Y, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL & Evans RM 1997 Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89 373-380.
69. O'Donnell AL & Koenig RJ 1990 Mutational analysis identifies a new functional domain of the thyroid hormone receptor. Molecular Endocrinology 4 715-720.
70. Ogryzko VV, Schiltz RL, Russanova V, Howard BH & Nakatani Y 1996 The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87 953-959.
71. Onate SA, Tsai SY, Tsai M-J & O'Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270 1354-1357.
72. Parker MG 1993 Steroid and related receptors. Current Opinion in Cell Biology 5 499-504.
73. Pennisi E 1996 Expanding the eukaryote's cast of chaperons. Science 274 1613-1614.
74. Pfahl M 1993 Nuclear receptor AP-1 interaction. Endocrine Reviews 14 651-658.
75. Philips A, Chalbos D & Rochefort H 1993 Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. Journal of Biological Chemistry 268 14103-14108.
76. Power RF, Mani SK, Codina J, Conneely OM & O'Malley BW 1991 Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254 1636-1639.
77. Pratt WB & Toft DO 1997 Steroid receptor interactions with heat shock proteins and immunophilin chaperons. Endocrine Reviews 18 306-360.
78. Rea D & Parker MG 1996 Effects of an exon-5 variant of the estrogen-receptor in MCF-7 breast-cancer cells. Cancer Research 56 1556-1563.
79. Reese JC & Katzenellenbogen BS 1991 Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells. Nucleic Acids Research 19 6595-6602.
80. Renaud J-P, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H & Moras D 1995 Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 378 681-689.
81. Roberts AB & Sporn MB 1992 Mechanistic interrelationships between two superfamilies: the steroid/retinoid receptors and transforming growth factor-β. In: Cancer Surveys, vol 14, pp 205-220. Ed. MG Parker. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
82. Saatcioglu F, Bartunek P, Deng T, Zenke M & Karin M 1993 A conserved C-terminal sequence that is deleted in v-ErbA is essential for the biological activities of c-ErbA (the thyroid hormone receptor). Molecular and Cellular Biology 13 3675-3685.
83. Saatcioglu F, Claret F-X & Karin M 1994 Negative transcriptional regulation by nuclear receptors. In: Seminars in Cancer Biology, vol 5, pp 347-359. Ed. M Parker. London: Academic Press.
84. Saatcioglu F, Lopez G, West BL, Zandi E, Feng W, Lu H, Esmaili A, Apriletti JW, Kushner PJ, Baxter JD & Karin M 1997 Mutations in the conserved C-terminal sequence in the thyroid hormone receptor dissociate hormone-dependent activation from interference with AP-1 activity. Molecular and Cellular Biology 17 4687-4695.
85. Sadovsky Y, Webb P, Lopez G, Baxter JD, Cavailles V, Parker MG & Kushner PJ 1995 Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein. Molecular and Cellular Biology 15 1554-1563.
86. Shemshedini L, Knauthe R, Sassone-Corsi P, Pornon A & Gronemeyer H 1991 Cell-specific inhibitory and stimulatory effects of Fos and Jun on transcription activation by nuclear receptors. EMBO Journal 10 3839-3849.
87. Shikama N, Lyon J & La Thangue NB 1997 The p300/CBP family: integrating signals with transcription factors and chromatin: Trends in Cell Biology 7 230-236.
88. Smith CL, Nawaz Z & O'Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Molecular Endocrinology 11 657-666.
89. Smith DF & Toft DO 1993 Steroid-receptors and their associated proteins. Molecular Endocrinology 74-11.
90. Soto AM, Justicia H,Wray JW & Sonnenscheine C 1991 p-Nonylphenol: an estrogenic xenobiotic released from 'modified' polystyrene. Environmental Health Perspectives 92 167-173.
91. Stein B & Yang MX 1995 Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κ and C/ EBPβ. Molecular and Cellular Biology 15 4971-4979.
92. Tasset D, Tora L, Fromental C, Scheer E & Chambon P 1990 Distinct classes of transcriptional activating domains function by different mechanisms. Cell 62 1177-1187.
93. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E & Chambon P 1989 The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59 477-487.
94. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK & Rosenfeld MG 1997 The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387 677-684.
95. Tzukerman MT, Esty A, Santisomere D, Danielian P, Parker MG, Stein RPJW & McDonnell DP 1994 Human estrogen-receptor transactivational capacity is determined by both cellular and promoter context and mediated by 2 functionally distinct intramolecular regions. Molecular Endocrinology 8 21-30.
96. Voegel JJ, Heine MJS, Zechel C, Chambon P & Gronemeyer H 1996 TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO Journal 15 101-108.
97. Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD & Fletterick RJ 1995 A structural role for hormone in the thyroid hormone receptor. Nature 378 690-697.
98. Webb P, Lopez GN, Uht RM & Kushner PJ 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Molecular Endocrinology 9 443-456.
99. Weis KE, Ekena K, Thomas JA, Lazennec G & Katzenellenbogen BS 1996 Constitutively active human estrogen-receptors containing amino-acid substitutions for tyrosine-537 in the receptor protein. Molecular Endocrinology 10 1388-1398.
100. White R, Jobling S, Hoare SA, Sumpter JP & Parker MG 1994 Environmentally persistent alkylphenolic compounds are estrogenic. Endocrinology 135 175-182.
101. White R, Sjöberg M, Kalkhoven E & Parker MG 1997 Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine. EMBO Journal 16 1427-1435.
102. Wurtz J-M, Bourguet W, Renaud J-P, Vivat V, Chambon P, Moras D & Gronemeyer H 1996 A canonical structure for the ligand-binding domain of nuclear receptors. Nature Structural Biology 3 87-94.
103. Yang NN, Venugopalan M, Hardikar S & Glasebrook A 1996 Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273 1222-1224.
104. Yang X-J, Ogryzko VV, Nishikawa J-I, Howard BH & Nakatani Y 1996 A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382 319-324.
105. Yao T-P, Ku G, Zhou N, Scully R & Livingston DM 1996 The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proceedings of the National Academy of Sciences of the USA 93 10626-10631.
106. Yeh S & Chang C 1996 Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in prostate cells. Proceedings of the National Academy of Sciences of the USA 93 5517-5521.
107. Zhang QX, Borg A, Wolf DM, Oesterreich S & Fuqua SA 1997 An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Research 57 1244-1249.
108. Zwijsen RML, Wientjens E, Klompmaker R, van der Sman J, Bernards R & Michalides RJAM 1997 CDK-indepcndent activation of estrogen receptor by cyclin D1. Cell 88 405-415.